ter Avest, Mendy http://orcid.org/0000-0001-5757-4919
Langemeijer, Saskia M.C
Blijlevens, Nicole M.A.
van de Kar, Nicole C.A.J.
ter Heine, Rob
Article History
Received: 31 May 2023
Accepted: 3 March 2024
First Online: 8 March 2024
Declarations
:
: NvdK has received a consultancy fee from Roche Pharmaceuticals and Novartis and is a sub-investigator in the APL2-C3G trial, Apellis. RtH has received research funding from AMGEN. The other authors declare that they have no conflict of interest. This article does not contain any studies with human participants or animals performed by any of the authors.